Indicators of therapy tolerability
| Group . | (1) . | (2) . | (3) . | (4) . | Total . | P value 4-group* . | Group (1) vs (4)† . |
|---|---|---|---|---|---|---|---|
| RHCVAD, n = 83, N (%) . | RHCVAD + HDT/ASCR, n = 21, N (%) . | RCHOP, n = 29, N (%) . | RCHOP + HDT/ASCR, n = 34, N (%) . | ||||
| < 6 cycles of induction therapy received | |||||||
| No | 61 (79) | 7 (33) | 21 (84) | 31 (94) | 120 (77) | ||
| Yes | 16 (21) | 14 (67) | 4 (16) | 2 (6) | 36 (23) | < .001‡§ | .09§ |
| Unknown | 3 | 0 | 1 | 1 | 5 | ||
| Complication(s) of first-line therapy | |||||||
| No | 33 (46) | 4 (25) | 23 (79) | 26 (84) | 86 (58) | ||
| Yes | 38 (53) | 12 (75) | 6 (21) | 5 (16) | 61 (41) | < .001ठ| < .001ठ|
| Unknown | 12 | 5 | 0 | 3 | 20 |
| Group . | (1) . | (2) . | (3) . | (4) . | Total . | P value 4-group* . | Group (1) vs (4)† . |
|---|---|---|---|---|---|---|---|
| RHCVAD, n = 83, N (%) . | RHCVAD + HDT/ASCR, n = 21, N (%) . | RCHOP, n = 29, N (%) . | RCHOP + HDT/ASCR, n = 34, N (%) . | ||||
| < 6 cycles of induction therapy received | |||||||
| No | 61 (79) | 7 (33) | 21 (84) | 31 (94) | 120 (77) | ||
| Yes | 16 (21) | 14 (67) | 4 (16) | 2 (6) | 36 (23) | < .001‡§ | .09§ |
| Unknown | 3 | 0 | 1 | 1 | 5 | ||
| Complication(s) of first-line therapy | |||||||
| No | 33 (46) | 4 (25) | 23 (79) | 26 (84) | 86 (58) | ||
| Yes | 38 (53) | 12 (75) | 6 (21) | 5 (16) | 61 (41) | < .001ठ| < .001ठ|
| Unknown | 12 | 5 | 0 | 3 | 20 |
Indicators of therapy tolerability were examined including receipt of < 6 cycles of induction therapy or those who had a complication of therapy that required inpatient care or hospitalization. Patients progressing on therapy (n = 6) were excluded from all analyses involving cycles of therapy. Abbreviations are explained in Table 1.
“P value 4-group” refers to the statistical significance across all four therapy groups.
“Group 1 vs 4” refers to the P value of the association between patients in the RHCVAD and RCHOP + HDT/ASCR therapy groups.
P < .001.
Fisher exact test.